NO994303L - Crystalline hydrated sodium salt of (E) -4,6-dichloro-3- (2-oxo-1-phenylpyrrolidin-3-ylidenomethyl) -1H-indole-2-carboxylic acid - Google Patents
Crystalline hydrated sodium salt of (E) -4,6-dichloro-3- (2-oxo-1-phenylpyrrolidin-3-ylidenomethyl) -1H-indole-2-carboxylic acidInfo
- Publication number
- NO994303L NO994303L NO994303A NO994303A NO994303L NO 994303 L NO994303 L NO 994303L NO 994303 A NO994303 A NO 994303A NO 994303 A NO994303 A NO 994303A NO 994303 L NO994303 L NO 994303L
- Authority
- NO
- Norway
- Prior art keywords
- sodium salt
- ylidenomethyl
- phenylpyrrolidin
- indole
- dichloro
- Prior art date
Links
- 159000000000 sodium salts Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
En krystallinsk hydrert form av natriumsaltet til forbindelsen med formel (I), fremgangsmåter for fremstilling derav og anvendelse i terapi er beskrevet.A crystalline hydrated form of the sodium salt of the compound of formula (I), processes for its preparation and use in therapy is described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704498.6A GB9704498D0 (en) | 1997-03-05 | 1997-03-05 | Chemical compound |
| PCT/EP1998/001146 WO1998039327A1 (en) | 1997-03-05 | 1998-03-03 | Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994303D0 NO994303D0 (en) | 1999-09-03 |
| NO994303L true NO994303L (en) | 1999-11-03 |
Family
ID=10808697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994303A NO994303L (en) | 1997-03-05 | 1999-09-03 | Crystalline hydrated sodium salt of (E) -4,6-dichloro-3- (2-oxo-1-phenylpyrrolidin-3-ylidenomethyl) -1H-indole-2-carboxylic acid |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0966463A1 (en) |
| JP (1) | JP2001513796A (en) |
| KR (1) | KR20000075907A (en) |
| CN (1) | CN1249750A (en) |
| AP (1) | AP9901637A0 (en) |
| AR (1) | AR011178A1 (en) |
| AU (1) | AU6825198A (en) |
| BG (1) | BG103779A (en) |
| BR (1) | BR9808305A (en) |
| CA (1) | CA2282851A1 (en) |
| CO (1) | CO4940415A1 (en) |
| EA (1) | EA199900710A1 (en) |
| EE (1) | EE9900387A (en) |
| GB (1) | GB9704498D0 (en) |
| HR (1) | HRP980114A2 (en) |
| HU (1) | HUP0002109A2 (en) |
| ID (1) | ID24207A (en) |
| IL (1) | IL131489A0 (en) |
| IS (1) | IS5166A (en) |
| NO (1) | NO994303L (en) |
| NZ (1) | NZ337315A (en) |
| OA (1) | OA11154A (en) |
| PE (1) | PE51399A1 (en) |
| PL (1) | PL335652A1 (en) |
| SK (1) | SK119699A3 (en) |
| TR (1) | TR199902117T2 (en) |
| WO (1) | WO1998039327A1 (en) |
| YU (1) | YU43499A (en) |
| ZA (1) | ZA981791B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704499D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9825988D0 (en) | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AU2018284335A1 (en) | 2017-06-12 | 2020-01-30 | Glytech Llc. | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321221D0 (en) * | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
-
1997
- 1997-03-05 GB GBGB9704498.6A patent/GB9704498D0/en active Pending
-
1998
- 1998-03-03 CO CO98011404A patent/CO4940415A1/en unknown
- 1998-03-03 AR ARP980100948A patent/AR011178A1/en unknown
- 1998-03-03 NZ NZ337315A patent/NZ337315A/en unknown
- 1998-03-03 CN CN98803053A patent/CN1249750A/en active Pending
- 1998-03-03 ID IDW990976A patent/ID24207A/en unknown
- 1998-03-03 JP JP53813598A patent/JP2001513796A/en active Pending
- 1998-03-03 YU YU43499A patent/YU43499A/en unknown
- 1998-03-03 ZA ZA9801791A patent/ZA981791B/en unknown
- 1998-03-03 PL PL98335652A patent/PL335652A1/en unknown
- 1998-03-03 BR BR9808305-8A patent/BR9808305A/en not_active Application Discontinuation
- 1998-03-03 EA EA199900710A patent/EA199900710A1/en unknown
- 1998-03-03 EE EEP199900387A patent/EE9900387A/en unknown
- 1998-03-03 WO PCT/EP1998/001146 patent/WO1998039327A1/en not_active Ceased
- 1998-03-03 CA CA002282851A patent/CA2282851A1/en not_active Abandoned
- 1998-03-03 AU AU68251/98A patent/AU6825198A/en not_active Abandoned
- 1998-03-03 IL IL13148998A patent/IL131489A0/en unknown
- 1998-03-03 HU HU0002109A patent/HUP0002109A2/en unknown
- 1998-03-03 TR TR1999/02117T patent/TR199902117T2/en unknown
- 1998-03-03 AP APAP/P/1999/001637A patent/AP9901637A0/en unknown
- 1998-03-03 KR KR1019997007987A patent/KR20000075907A/en not_active Withdrawn
- 1998-03-03 PE PE1998000149A patent/PE51399A1/en not_active Application Discontinuation
- 1998-03-03 SK SK1196-99A patent/SK119699A3/en unknown
- 1998-03-03 EP EP98913613A patent/EP0966463A1/en not_active Withdrawn
- 1998-03-04 HR HR9704498.6A patent/HRP980114A2/en not_active Application Discontinuation
-
1999
- 1999-08-27 IS IS5166A patent/IS5166A/en unknown
- 1999-09-02 OA OA9900201A patent/OA11154A/en unknown
- 1999-09-03 NO NO994303A patent/NO994303L/en not_active Application Discontinuation
- 1999-10-04 BG BG103779A patent/BG103779A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6825198A (en) | 1998-09-22 |
| ID24207A (en) | 2000-07-13 |
| BG103779A (en) | 2000-06-30 |
| AR011178A1 (en) | 2000-08-02 |
| SK119699A3 (en) | 2000-05-16 |
| TR199902117T2 (en) | 2000-03-21 |
| KR20000075907A (en) | 2000-12-26 |
| JP2001513796A (en) | 2001-09-04 |
| PE51399A1 (en) | 1999-06-07 |
| IL131489A0 (en) | 2001-01-28 |
| CO4940415A1 (en) | 2000-07-24 |
| CA2282851A1 (en) | 1998-09-11 |
| AP9901637A0 (en) | 1999-09-30 |
| EA199900710A1 (en) | 2000-04-24 |
| EE9900387A (en) | 2000-04-17 |
| CN1249750A (en) | 2000-04-05 |
| NZ337315A (en) | 2001-02-23 |
| HUP0002109A2 (en) | 2001-04-28 |
| BR9808305A (en) | 2000-05-16 |
| GB9704498D0 (en) | 1997-04-23 |
| EP0966463A1 (en) | 1999-12-29 |
| HRP980114A2 (en) | 1998-12-31 |
| IS5166A (en) | 1999-08-27 |
| PL335652A1 (en) | 2000-05-08 |
| YU43499A (en) | 2000-12-28 |
| OA11154A (en) | 2003-04-16 |
| WO1998039327A1 (en) | 1998-09-11 |
| ZA981791B (en) | 1999-09-03 |
| NO994303D0 (en) | 1999-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2260337A1 (en) | Therapeutic agents | |
| TW200407287A (en) | A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I) | |
| TR200200579T2 (en) | Amino-thyrazolpyridine derivatives. | |
| TR199700844T1 (en) | Pyrazolyl-Benzoil T�revleri. | |
| DK0977741T3 (en) | Substituted phenyl derivatives, their preparation and use | |
| MXPA02003977A (en) | INHIBITORS OF agr;L. | |
| NO20022558L (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor | |
| IL135921A (en) | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity | |
| NO996108L (en) | 9 oksinerytromycinderivater | |
| DE69924292D1 (en) | PYRAZOL COMPOUNDS AND ITS USE | |
| TR200002605T2 (en) | Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors | |
| GB9514518D0 (en) | Guanidine salt inhibitors of NO synthase and cyclooxygenase | |
| TR199700206A2 (en) | Fluoralkyl- and fluoroalkoxy-substituted heterocyclic bradykinin-antagonists, process for their manufacture and their use. | |
| NO964348L (en) | CCK or gastrin modulating 5-heterocyclic-1,5-benzodiazepines | |
| TR200001909T2 (en) | Matrix metalloprosthesis inhibitors. | |
| NO994303L (en) | Crystalline hydrated sodium salt of (E) -4,6-dichloro-3- (2-oxo-1-phenylpyrrolidin-3-ylidenomethyl) -1H-indole-2-carboxylic acid | |
| PL348721A1 (en) | Use of phosphonoformic acid derivatives for treating infections | |
| AU4944899A (en) | New pharmaceutically active compounds | |
| JO2240B1 (en) | Process for the preparation of thiazolidinedione derivatives | |
| PT1104419E (en) | AZABICYCLOHEPTAN DERIVATIVES SUBSTITUTED IN NITROGEN ITS PREPARATION AND UTILIZATION | |
| NZ329716A (en) | Sulfonamide substituted derivatives and medicaments thereof | |
| PL348354A1 (en) | Use of phosphonoformic acid derivatives for treating infections | |
| EE200200227A (en) | Type 1 Crystals of Sodium Hydrogen Ion Inhibitor | |
| ZA9810361B (en) | Heterocyclic compounds having MMP and TNF inhibitory activity. | |
| ATE56445T1 (en) | PHARMACOLOGICALLY ACTIVE PROPIONYLANILIDES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |